My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 532291 | NSE: KOPDRUGS | Pharmaceuticals & Drugs | Small Cap
1. Is a good quality company?
Data is not available for this company.
2. Is undervalued or overvalued?
No data found
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'02 | Mar'03 | Mar'04 | Sep'05 | Mar'06 | Sep'07 | Sep'08 | Mar'10 | Mar'11 | Mar'12 | TTM | |||
| ROCE % ⓘ | 6.1% | 5.5% | 1.8% | -24.1% | -6.8% | -4.8% | -14.2% | -21.4% | -105.3% | -129.4% | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 204 | 193 | 124 | 106 | 110 | 113 | 56.8 | 25.6 | 28.4 | 26.5 | 0 | ||
| YoY Gr. Rt. % | - | -5.2% | -35.9% | -14.7% | 4.4% | 2.3% | -49.7% | -55% | 11% | -6.8% | - | ||
| Adj EPS ⓘ | 2.1 | 1.4 | -1.8 | -17.2 | -13.5 | -5.4 | -8.5 | -6 | -23.4 | -7.2 | -5.9 | ||
| YoY Gr. Rt. % | - | -31.7% | -228.6% | NA | NA | NA | NA | NA | NA | NA | - | ||
| BVPS (₹) ⓘ | 35.5 | 36.1 | 35.2 | 6.9 | 0.3 | -0.1 | 16.4 | 6.2 | -17.5 | -24.6 | -42.5 | ||
| Adj Net Profit ⓘ | 3.4 | 2.4 | -3 | -28.9 | -22.6 | -9 | -20.4 | -14.5 | -56.3 | -17.2 | -14 | ||
| Cash Flow from Ops. ⓘ | -10.6 | 34.9 | 14.2 | 6.4 | -1.9 | 1.7 | -6.3 | 2.2 | 1.6 | 6.8 | - | ||
| Debt/CF from Ops. ⓘ | -7.2 | 2 | 5 | 7.9 | -84.3 | 32.2 | -10.2 | 17.7 | 38.4 | 8.9 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -20.3% | -24.9% | -22.5% | -6.8% | ||||||||
| Adj EPS ⓘ | -214.9% | NA | NA | NA | ||||||||
| BVPSⓘ | -196% | -343.1% | -214.6% | NA | ||||||||
| Share Price | - | - | - | - | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'02 | Mar'03 | Mar'04 | Sep'05 | Mar'06 | Sep'07 | Sep'08 | Mar'10 | Mar'11 | Mar'12 | TTM | ||
| Return on Equity % ⓘ | 4.1 | 2.6 | -3.3 | -64.7 | -31.5 | -104 | -104.5 | -70.2 | 573.9 | 34 | 17.6 | |
| Op. Profit Mgn % ⓘ | 9.8 | 8.2 | 10.1 | -11.7 | -6.2 | -6.4 | -14.9 | -26.4 | -57.6 | -7.8 | NAN | |
| Net Profit Mgn % ⓘ | 1.7 | 1.2 | -2.4 | -27.3 | -20.4 | -8 | -35.9 | -56.5 | -198.1 | -65 | -INF | |
| Debt to Equity ⓘ | 0.9 | 0.8 | 0.8 | 1.8 | 3 | -308.8 | 1.6 | 2.6 | -1.4 | -1 | - | |
| Working Cap Days ⓘ | 147 | 142 | 182 | 127 | 328 | 129 | 298 | 211 | 166 | 107 | 0 | |
| Cash Conv. Cycle ⓘ | 62 | 63 | 58 | 39 | 90 | 22 | -37 | -60 | -56 | -18 | 0 | |
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -5.9 | - |
| TTM Sales (₹ Cr.) | 0 | - |
| BVPS (₹.) ⓘ | -42.5 | - |
| Reserves (₹ Cr.) ⓘ | -126 | - |
| P/BV ⓘ | -0.05 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 2.14 / 2.14 |
| All Time Low / High (₹) | 1.61 / 413.35 |
| Market Cap (₹ Cr.) | 5.1 |
| Equity (₹ Cr.) | 24 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.
KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.
KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.
Milestones:
2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.
2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.
Products:
1. Finished Dosage Forms
• Antibiotics/Antibacterial s• Anti-Malarial • Cadiovasculars • Pain Management • Anthelminthics
2. Active Pharmaceutical Ingredients
• Anti-hypertensives • Macrolides • Taste Masked • Cephalosporins
Subsidiary:
• Kopran Research Laboratories
Group companies:
• Oriental Containers • United Shippers • Shinrai Toyota • Claridge Moulded Fibre • Kopran
Alliances:
• Gujarat Themis Biosyn • Kampala Pharmaceutical Industries, Uganda
Strategic Business Units:
• Finished Dosage Forms
• Active Pharmaceutical Ingredients
• Research & Development
• Kopran Laboratories
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
